Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver

Pharmacogenomics Journal

Volumn 8, Issue 2, 2008, Pages 152-161

  Ramirez J ^a   Mirkov, S ^a   Zhang, W ^a   Chen, P ^a   Das, S ^a   Liu, W ^a   Ratain, M J ^a   Innocenti, F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER FUNCTION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LIVER; PHENOTYPE; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 40949130482     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500454     Document Type: Article

References (52)

1. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
2. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-581.
3. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
4. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
5. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacagenet Genomics 2005; 15: 295-301.
6. Bhasker R, McKinnon W, Stone A, Lo A, Kubota T, Ishizaki T et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-685.
7. Holthe M, Rakvag TN, Klepstad P, Idle JR, Kaasa S, Krokan HE et al Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: Identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to. morphine glucuronidation in cancer patients. Pharmacogenomics 12003; 3: 17-26.
8. Sawyer MB, Innocenti F, Das S, eng C, Ramirez J, Pantle-Fisher FH et al. A pharmacogenetic study uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566-574.
9. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q et al Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14 501-515.
10. Girard H, Villeneuve L, Court M, Fortier LC, Caron P, Hao Q et al. The novel UGT1A9 intronic polymorphism 1399 appears as a predictor of SN-38 glucuronidation levels in liver microsomes. Drug Metab Dispos 2006; 34: 1220-1228.
11. Ishii Y, Hansen AJ, Mackenzie PI. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Phormacol 2000; 57: 940-947.
12. Gregory PA, Mackenzie PI. The homeodomain Pbx2-Pbx1 complex modulates hepatocyte nuclear factor 1alpha-mediated activation of the UDP-glucuronosyltransferase 2B17 gene. Mol Pharmacol 2002; 62 154-161.
13. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. Mol Pharmacol 2004, 65: 953-963.
14. Mackenzie PI, Gardner-Stephen DA, Gregory PA, Ishii Y, Lewinsky RH. Mechanisms of UDP-Glucuronosyltransferase Gene Regulation. International Workshop on Glucuronidation: University of Dundee, Scotland, 2004.
15. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378-1381.
16. Gardner-Stephen DA, Gregory PA, Mackenzie PI. Identification and characterization of functional he atocyte nuclear factor 1-binding sites in UDP-gluculronosyltransferase genes. Methods Enzymol 2005; 400: 22-46.
17. Zhou J, Zhang J, Xie We. Xenobiotic nuclear receptor-mediated regulation of UDP-glucoronosyl-transferases. Curr Drug Metab 2005; 6: 289-298.
18. Cereghini S. Liver-enriched transcription factors and hepatocyte, differentiation. FASEB J 1996; 10: 267-282.
19. Bernard P, Goudonnet H, Artur Y, Desvergne B, Wahl W, Activation of the mouse TATA-less and human TATA-containing UDP-glucorunosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Mol Pharmacol 1999; 66: 526-536.
20. Chiu KC, Chuang LM, Ryu JM, Tsai GP, Saad MF. The 127L amino acid polymorphism of hepatic nuclear factor-1alpha is associated with insulin resistance. J Clin Endocrinol Metab 2000; 85: 2178-2183.
21. Urhammer SA, Moller AM, Nyholm B, Ekstrom CT, Eiberg R, Clausen JO et al. The effect of two frequent amino acid variants of the hepatocyte nuclear factor-1 alpha gene on estimates of the pacreatic beta-cell function in Caucasian glucose-tolerant first-degree relatives of type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 3992-3995.
22. Babaya N, Ikegami H, Fujisawa T, Nojima K, Itoi-Babaya M, Inoue K et al. Association of 127L polymorphism of hepatocyte nuclear factor-1 alpha gene with high-density lipoprotein cholesterol level. J Clin Endocrinol Metab 2003; 88: 2548-2551.
23. Winter WE. Molecular and biochemical analysis of the MODY syndromes. Pediatr Diabetes 2000; 1: 88-117.
24. Toide K, Takahashi Y, Yamazaki H, Terauchi Y, Fujii T, Parkinson A et al. Hepatocyte nuclear factor-lalpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos 2002; 30: 613-615.
25. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, Fisher RA. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences. Hepotology 1999; 30: 476-484.
26. Sutherland L, Ebner T, Burchell B. The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 1993; 45: 295-301.
27. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ et al. UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: 1. Identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Ex Ther 2005; 313: 1331-1339.
28. Winckler W, Burtt NP, Holmkvist J, Cervin C, de Bakker PI, Sun M et al. Association of common variation in the HNF1alpha gene region with risk of type 2 diabetes. Diabetes 2005; 54: 2336-2342.
29. Bach I, Yaniv M. More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeoprotein family are generated by alternative RNA processing. EMBO J 1993; 13: 4229-4242.
30. Fang JL, Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7, 8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 2004; 13: 102-109.
31. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmocogenetics 2002; 12 725-733.
32. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576-582.
33. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
34. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14: 329-332.
35. Fleischmann R, Remmer H, Starz U. Induction of cylochrome P-488 isoenzymes and related glucuronyltransferases in the human liver by cigarette smoking. Eur J Clin Pharmacol 1986; 30: 475-480.
36. Walle T, Walle UK, Coward TD, Conradi EC, Gaffney TE. Selective induction of propranolol metabolism by smoking: Additional effects on renal clearance of metabolites. J Pharmacol Exp Ther 1987; 241 928-933.
37. Doodstar H, Grant MH, Melvin WT, Wolf CR, Burke MD. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol 1993; 46: 629-635.
38. Ritter JK, Kessler FK, Thompson MT, Groove AD, Auyeung DJ, Fisher RA. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences. Hepatology 1999; 30: 476-484.
39. Kardon T, Coffey MT, Banhegyi G, Conley AA, Burchell Bj Mandl J et al Transcriptional induction of bilirubin UDP-glucuronosyltransferase by ethanol in rat liver. Alcohol 2000; 21: 251-257.
40. Ramirez J, komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG.et al. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics 2006; 16: 79-86.
41. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.
42. Brierley CH, Senafi SB, Clarke D, Hsu MH, Johnson EF, Burchell B. Regulation of the human bilirubin UDP-glucuronosyltransferase gene. Adv Enzyme Regul 1996; 36: 85-97.
43. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH et al The phenobarbital response enhancer module in the human bilirubin UDP glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001; 33: 1232-1238.
44. Sugatani J, Yamakawa K, Tonda E, Nishitani 5, Yoshinari K, Degawa M et al. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 2004; 67: 989-1000.
45. Ban N, Yamada Y, Someya Y, Miyawaki K, Ihara Y, Hosokawa M et al. Hepatocyte nuclear factor-1 alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. Diabetes 2002; 51 1409-1418.
46. Soutoglou E, Papafotiou G, Katrakili N, Talianidis I. Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J Biol Chem 2000; 275: 12515-12520.
47. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD et al. Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 2002; 277: 31909-31917.
48. Kritis AA, Ktistaki E, Barda D, Zannis VI, Talianidis I. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acid Res 1993; 21: 5882-5889.
49. Ktistaki E, Talianidis I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1. Science 1997; 277: 109-112.
50. Eeckhoute J, Formstecher P, Laine B. Hepatocyte nuclear factor 4alpha enhances the hepatocyte nuclear factor 1alpha-mediated activation of transcription. Nucleic Acids Res 2004; 32: 2586-2593.
51. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamika A et al Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol 2005; 67: 241-249.
52. The R package. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2005. ISBN 3-900051-07-0, URL http://www.R-project.org.